Objective To study the disposition of serum testosterone and seven of its metabolites before and after 2 days of an intramuscular dose (500 mg) of testosterone enanthate in relation to the phosphodiesterase (PDE7B) and the uridine 5 0 -diphospho-glucuronosyltransferase (UGT2B17) genotypes.
Objective To study the disposition of serum testosterone and seven of its metabolites before and after 2 days of an intramuscular dose (500 mg) of testosterone enanthate in relation to the phosphodiesterase (PDE7B) and the uridine 5 0 -diphospho-glucuronosyltransferase (UGT2B17) genotypes.
Methods Patients were genotyped for UGT2B17 deletion polymorphism and single nucleotide polymorphisms in the PDE7B gene. The involvement of PDE7B in hydrolysis of enanthate was assessed in human liver homogenates.
Results Genetic variation in the PDE7B gene was found to be associated with the serum level of testosterone. Individuals homozygous for PDE7B rs7774640 G allele had a smaller increase (2.5-fold) in the serum testosterone levels compared with carriers of the A allele (3.9-fold, P = 0.0006). In addition, genetic variation in the PDE7B gene significantly influences the testosterone/ epitestosterone ratio, a biomarker of testosterone doping. Our in-vitro incubation studies confirmed that PDE7B serves as a catalyst of the hydrolysis of testosterone enanthate. The UGT2B17 deletion polymorphism did not show any significant association with serum testosterone levels or the other androgen metabolites investigated.
Conclusion
We have shown that PDE7B is involved in the hydrolysis of testosterone enanthate and that genetic variation in the PDE7B gene is a determinant of the systemic levels of testosterone after administration of testosterone enanthate. It is reasonable to believe that the genetic variation in testosterone bioavailability may be correlated to varying effects of this androgen, whether it is used for replacement therapy or abused in doping. Thus our results may be important to consider in doping test programmes and in therapeutics with androgens and other esterified drugs. 
Introduction
Testosterone is responsible for normal growth and development of the male reproductive system and for maintenance of secondary sex characteristics. It has been in clinical use for approximately 60 years, and testosterone replacement therapy in men with hypogonadism is a widespread and growing practice. There are a number of pharmaceutical formulations approved for this treatment including buccal tablets, oral capsules, intramuscular depot preparations and gels (reviewed in [1] ). To date, injectable testosterone esters, that is, testosterone enanthate and testosterone decanoate, are the most common formulations used. These drugs have a prolonged depot action due to slow release of the lipophilic steroid ester from the injection site. The ester is hydrolyzed to active testosterone, but it is not known which esterases are involved.
As administration of exogenous androgens may enhance muscle mass and strength, these drugs are popular among young people and in the society and in sports [2] . This study programme for testosterone doping is based on determination of the urinary ratio of testosterone glucuronide and epitestosterone glucuronide, often referred to as the T/E ratio [3, 4] . International rules for doping in sports stipulate that a T/E ratio above 4.0 gives reason to suspect testosterone doping and such samples must be subjected to further analyses for confirmation.
The major enzyme responsible for testosterone glucuronidation is uridine 5 0 -diphospho-glucuronosyltransferase (UGT2B17) [5, 6] . A gene deletion polymorphism of Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.pharmacogeneticsandgenomics.com).
UGT2B17 [7] was shown by us to be concordant with the rate of urinary testosterone excretion [5] . We were subsequently able to show that testosterone doping test results are highly dependent on the UGT2B17 deletion genotype as investigated in healthy volunteers [8, 9] . Individuals homozygous for the UGT2B17 deletion polymorphism (del/del) have a markedly compromised testosterone glucuronide excretion capacity, both physiologically [5] and after testosterone administration [8] . Therefore, it is conceivable to assume that testosterone concentration in the circulation would be higher in patients devoid of the enzyme (del/del) compared with those with the UGT2B17 enzyme (del/ins, ins/ins), after testosterone administration.
Here, we have investigated the serum levels of testosterone and seven of its metabolites in 51 patients before and after 2 days of a single intramuscular dose of testosterone enanthate. Interestingly, a large interindividual variation and a bimodal distribution of the serum androgen levels were observed on day 2 indicating a genetic influence on the bioavailability. Affymetrix (Mercury Park, UK) analysis identified the phosphodiesterase (PDE7B) gene as potentially causative. Genotyping of selected single nucleotide polymorphisms (SNPs) in the PDE7B gene disclosed the PDE7B as a determinant of testosterone serum levels. Our data are further supported by studies of ester cleavage of testosterone enanthate in human liver homogenates.
Materials and methods
Study participants included 51 healthy male volunteers aged between 18 and 50 years (mean: 30.6 ± 7.0 years). All participants underwent a medical examination including laboratory tests before enrolment to exclude the possibility of any infections, hepatic or renal disease. Medical records were taken and participants were excluded if they had taken drugs that interfere with the synthesis, metabolism or excretion of steroids. Three participants reported to have taken antidepressants (paroxetin, escitalopram and sertralin) throughout the study. One participant took antibiotics (metronidazole and phenoxymethylpenicillin) on days 11-15. Three participants took one or two doses of nonsteroidal anti-inflammatory drugs (diclofenac and ibuprofen) and one patient took one dose of acetylsalicylic acid during the course of the study. Further inclusion criteria included negative screening tests for illegal drugs, anabolic androgenic steroids, HIV, and hepatitis B or C virus. For inclusion it was also required that the participant was not a member of any organization belonging to the Swedish Sports Confederation, or had had a malignancy within the past 5 years, or an allergy to the study substance. All participants gave informed consent consistent with the approval of the Ethics Review Board in Stockholm.
The participants were given 500 mg of testosterone enanthate as a single intramuscular dose (TestovironDepot, kindly provided by Schering Nordiska AB, Solna Sweden) equivalent to 360 mg testosterone. Before administration (day 0) and on day 2, serum samples were collected for analyses. All samples were collected between 07 : 00 h and 11 : 00 h. Moreover, morning urine samples were collected on days 0, 1-9, 11, 13 and 15. Adverse drug reactions were monitored from the time of screening until day 15 after administration of testosterone. The study was conducted according to the Helsinki declaration and the ICH Harmonised Tripartite Guideline for Good Clinical Practice.
Assessment of steroids in serum
Serum concentrations of testosterone, dihydrotestosterone, androsterone, 5a-androstane-3b,17b-diol and the glucuronidated androgen metabolites 5a-androstane-3a,17b-diol-17-glucuronide (3a-Adiol-17G), 5a-androstane-3a, 17b-diol-3-glucuronide (3a-Adiol-3G), androsteroneglucuronide (ADT-G), and etiocholanolone glucuronide (Etio-G) were analysed as described earlier [10, 11] .
Genome-wide analysis
Ten DNA samples obtained from individuals with high (N = 5; > 20 ng/ml) and low serum (N = 5; < 10 ng/ml) testosterone levels on day 2 were analysed using Affymetrix. DNA was prepared using Qiamp DNA Blood Mini Kit (Hilden, Germany). The extracted DNA samples were analysed by Bioinformatics and Expression Analysis Core Facility, Karolinska Institutet, where they were processed and hybridized to Affymetrix Human Mapping SNP6.0.
Sequence analysis
One hundred nanogram of genomic DNA obtained from each participant (N = 10) were used in PCR reactions together with elongation DNA polymerase according to the manufacturer's manual (Invitrogen, Carlsbad, California, USA). The PCR products were purified using PCR purification kit (Macherey-Nagel, Düren, Germany) and the promoter region, and exons 1-5 were sequenced in both directions using the following oligonucleotides: exon 1, promoter region, forward 5
Genotyping of phosphodiesterase and uridine 5 0 -diphospho-glucuronosyltransferase polymorphisms Two SNPs, rs7774640 and rs4896187, in the intron 1 region of PDE7B were investigated by 5 0 nuclease activity method using Taqman SNP Genotyping Assays C__1843374_10 and C__1843403_10 (Applied Biosystems, Foster City, California, USA). The PCR reaction was carried out in 25 ml volume including 25 ng genomic DNA, 2 Â Taqman universal master mix, and run on an ABI 7500 Fast (Applied Biosystems). The PCR profile consisted of an initial denaturation step of 951C for 10 min followed by 40 cycles of denaturation for 15 s and annealing/elongation at 601C for 1 min. The UGT2B17 deletion polymorphism was assayed by real-time PCR analysis as described earlier [8] .
Urinary testosterone/epitestosterone ratio
The urinary levels of T/E were determined by gas chromatography-mass spectrometry after hydrolysis of the conjugates with b-glucuronidase [12] . The morning T/E ratio was monitored for 15 days after the testosterone administration [8] .
In-vitro studies in liver homogenates
Fourteen human liver homogenate samples were obtained from Caucasian donors to our human liver bank (approved by the Ethics Review Board in Stockholm/at Karolinska Institutet). The liver samples were homogenized in 50 mmol/l potassium phosphate buffer (pH 7.4) and stored at -801C until use. The protein concentration was determined according to Lowry et al. [13] . Testosterone enanthate was dissolved in ethanol to a final concentration of 5 mmol/l and diluted in 50 mmol/l Tris-HCl buffer (pH 7.4). The incubation was performed at 371C using 10 mmol/l testosterone enanthate and 20 ml liver homogenate. At 1, 2, 4 and 8 min, the reaction mixture was stopped by immediate freezing. Testosterone esterase activity was determined by monitoring the testosterone formation by high-performance liquid chromatography as described by Narayanan et al. [14] with slight modifications. The analyses were carried out by high-performance liquid chromatography (231 XL Sampling injector, Gilson, P580 Pump, Dionex, Middleton, Wisconsin, USA) using a Zorbax SB-CN column (150 Â 4.6 mm inner diameter, 5 mm; Agilent Technologies, Palo Alto, California, USA). The mobile phase consisted of acetonitrile and ammonium phosphate buffer (50 mmol/l, pH 4.5; 30 : 70) and the flow rate was 1 ml/min. Testosterone was detected by ultraviolet at 250 nmol/l (Lambda 1010, Bischoff, Leonberg, Germany). The inhibition studies were carried out by adding increasing concentrations (10-1000 mmol/l) of BRL50481. BRL50481 was dissolved in dimethyl sulfoxide and the final dimethyl sulfoxide concentration was 0.5% in all assays. The inhibition of hydrolyse activity was expressed as the percentage of control activity.
Data analysis
The statistical analyses were carried out using GraphPad Prism Software version 4.03 (GraphPad, San Diego, California, USA). The serum levels of steroid metabolites before and after testosterone administration were compared by paired Student t-test. The increase and the differences in serum steroid levels between PDE7B genotypes and UGT2B17 deletion polymorphism were compared by unpaired Student's t-test and analysis of variance. Spearman's rank-correlation coefficient was used in the evaluation of association between the body weight and testosterone serum levels.
Results

Serum steroid profile of exogenous testosterone
The serum levels of testosterone and the metabolites such as dihydrotestosterone, 5a-androstane-3b,17b-diol, ADT, Etio-G, 3a-Adiol-17G, 3a-Adiol-3G and ADT-G on days 0 and 2 are shown in Table 1 . On day 2, a significant increase in the serum concentrations of all androgens was observed. For most of the metabolites analysed an approximately 100% increase was observed, whereas for testosterone and 3a-Adiol-17G a 200% increase was observed. The concentrations of all metabolites were positively-associated with testosterone level both on days 0 and 2.
There was a large interindividual variation in serum testosterone level 2 days after testosterone administration. The level was associated with body mass on day 2 (R 2 = 0.16, P = 0.003). When the increase (nanogram/ millilitre) was corrected for body weight, the distribution of natural logarithms of serum testosterone level showed a multimodal (bi-modal or tri-modal) pattern (Fig. 1) , suggesting a genetic contribution to the interindividual variation in serum testosterone concentration.
Genetic analysis
The results from the Affymetrix analysis of five individuals each with low or high-rise in testosterone concentration yielded approximately 300 hits (Supplementary Table 1 , Supplemental digital content 1 http:// links.lww.com/FPC/A244). Of particular interest, 12 of the SNPs were localized in the PDE7B gene. Two of them 3b-Adiol, 5a-androstane-3b,17b-diol; 3a-Adiol-3G, 5a-androstane-3a,17b-diol-3-glucuronide; 3a-Adiol-17G, 5a-androstane-3a,17b-diol-17-glucuronide; ADT, androsterone; ADT-G, androsterone-glucuronide; DHT, dihydrotestosterone; Etio-G, etiocholanolone glucuronide. ***P < 0.0001.
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were randomly chosen (rs7774640 and rs4896187) for further analysis, and Taqman reactions (Applied Biosystems) were used to genotype all participants (N = 51). The PDE7B genotypes were in Hardy-Weinberg equilibrium. The two PDE7B polymorphisms investigated showed the same genotype distribution in all the individuals indicating that they are in linkage disequilibrium. Haplotype analysis indicated that all the intron 1 SNPs identified from the Affymetrix analysis were in linkage disequilibrium with each other (data not shown). Therefore, only the analysis of the rs7774640, an A>G substitution, is presented here.
Individuals homozygous for the PDE7B G allele displayed significantly lower total testosterone concentrations on day 2 (13.5 ng/ml ± standard deviation 8.0) than individuals with one or two A alleles (19.3 ng/ml ± standard deviation 6.7) (R 2 = 0.15, P = 0.0053) (Fig. 2a) . Individuals homozygous for the G allele showed a significantly smaller increase (2.5-fold increase) in serum testosterone levels compared with carriers of the A allele (3.9-fold increase) (R 2 = 0.22, P = 0.0006). As expected, the baseline testosterone levels were not dependent on the PDE7B genotype.
To investigate whether the intron PDE7B SNP was linked with any other polymorphism in the near coding/ regulatory region of the gene, the exons 1-5 and the core promoter were sequenced. However, no polymorphism was identified in the 20 individual alleles sequenced.
There was no association between the UGT2B17 deletion genotype and total testosterone serum level on day 0 or day 2 (Fig. 2b) . Subsequently, the increase in total testosterone serum levels 2 days after the testosterone dose did neither differ between the genotype panels nor was there any association between the serum concentrations of the glucuronidated metabolites, that is, Etio-G, 3a-Adiol-17G, 3a-Adiol-3G on day 0 or day 2 and the UGT2B17 deletion polymorphism (data not shown).
Inhibition studies
The esterase activity was determined in human liver homogenates by monitoring the release of testosterone from its enanthate salt. A peak in testosterone level was observed after 2 min (data not shown). To assess if PDE7B exhibits testosterone enanthate hydrolysis activity, inhibition studies using BRL 50481 (Sigma-Aldrich, St. Louis, Missouri, USA), a specific PDE7B/7A inhibitor, were carried out. BRL50481 was found to inhibit the testosterone formation in human liver homogenates in a concentration-dependent manner indicating that PDE7B is involved in the hydrolysis of the testosterone enanthate ester (Fig. 3) . 
Phosphodiesterase genotype and testosterone/ epitestosterone ratio
The T/E ratio, an important biomarker in international doping control programme, was monitored in the urine after testosterone administration. The T/E ratio was associated with the PDE7B polymorphism, that is, individuals homozygous for the PDE7B G allele had lower T/E ratio after testosterone administration. This may have clinical relevance in UGT2B17 del/del individuals who rarely reach the T/E cut-off value of 4 (Fig. 4a) . After the first 5 days of testosterone administration, del/del participants homozygous for the PDE7B G variant had lower T/E ratio compared with carriers of the PDE7B A allele (significant on days 1 and 2, P = 0.02 and 0.04, respectively). The opposite was found on days 13 and 15, A-carriers had lower T/E ratio compared with GG (P = 0.09 and 0.03, respectively). Also, among individuals expressing UGT2B17 enzyme the T/E ratio was significantly lower in individuals homozygous for PDE7B G allele compared with individuals homozygous for AG/AA on day 2 (P = 0.03), day 4 (P = 0.03) and day 5 (P = 0.009) (Fig. 4c ).
Discussion
The large interindividual variation in the increase of testosterone serum levels 2 days after a single dose observed by us may be ascribed to genetic variation in an esterase enzyme, as we suggested earlier [15] . Our hypothesis was supported by the Affymetrix hit at the PDE7B gene, which was subject to further investigation. Interestingly, the serum level of testosterone was associated with genetic variation in the PDE7B gene. Our findings were corroborated in experiments of human liver samples in which we observed an inhibition of the hydrolysis of testosterone enanthate by the PDE7B/7A specific inhibitor, BRL50485. To our knowledge this is the first time an enzyme involved in testosterone enanthate hydrolysis has been studied and identified. It is likely that other enzymes are also involved in the hydrolysis as there was a residual activity after inhibition of the specific PDE7B/7A inhibitor.
A multiple regression analysis showed that the body weight and PDE7B genotype together explained 36% of the variation observed in serum testosterone level 2 days after testosterone administration. Other factors are known to influence the release of depot drugs. Thus, it has been shown that the body fat may serve as a depot for injected steroids, resulting in a retarded release [16] . Moreover, exercise will increase the blood flow through the tissue near the site of injection and hence increase the release rate.
As we did not find any linkage between the investigated intronic SNPs of the PDE7B gene and the near coding sequence of the gene it is not likely that these intron 
del/del ins/del ins/ins
(a) Serum levels of testosterone in relation to the phosphodiesterase intron 1 G>A polymorphism before (day 0; filled bars) and after 2 days (day 2; dotted bars) of testosterone administration. The total level of serum testosterone was significantly higher in A-carriers (N = 27) compared with individuals homozygous for the G allele (N = 24) on day 2. (b) Serum levels of testosterone and uridine 5 0 -diphosphoglucuronosyltransferase deletion polymorphism before (day 0; filled bars) and after 2 days (day 2; dotted bars) of testosterone administration. The UGT2B17 deletion polymorphism was not associated with total serum testosterone levels on day 0 and day 2. Inhibition studies in human liver homogenates. Testosterone enanthate was incubated with human liver homogenates for 2 min and the formation of testosterone was monitored by high-performance liquid chromatography. When increasing concentration of phosphodiesterase specific inhibitor BRL50481 was added, a decrease in testosterone enanthate hydrolyse activity was observed. 329 SNPs are in close linkage disequilibrium with a coding SNP in the PDE7B gene. Moreover, a HapMap analysis also confirmed that the 12 intronic SNPs are in linkage disequilibrium and that they are not linked with a SNP in the coding or regulatory region of the PDE7B gene. In fact, there are over 4000 intronic SNPs in the PDE7B gene identified in the National Centre for Biotechnology Information SNP database to date, but no one has been associated with an altered phenotype. It is possible that the intronic SNPs modulate the abundance and/or stability of PDE7B specific mRNA and hence the protein expression.
PDE7B genotype and serum testosterone level
PDE7B is a cyclic AMP-specific PDE7B mediating degradation of intracellular cyclic AMP by hydrolysis and is highly expressed in the brain, heart and liver [17] [18] [19] . Zhang et al. [20] found that the peripheral blood mononuclear PDE7B was selectively overexpressed in chronic lymphocytic leukaemia, highlighting PDE7B as a potential therapeutic target in this disease. Our novel finding that PDE7B also exhibits activity towards exogenous substrates may have clinical pharmacological importance. Interestingly, PDE7B was recently identified as a candidate gene for treatment response to risperidone [21] .
In addition to our findings of a large variation in testosterone levels in healthy volunteers after testosterone administration, Di Luigi et al. [22] observed interindividual variation in testosterone levels in hypogonadal volunteers after testosterone treatment 1 week after intramuscular administration of testosterone enanthate. Other investigations have also described large differences in serum concentration of testosterone among patients after androgen replacement therapy in hypogonadal men [23, 24] . It is of great interest to identify the genetic reasons for the variation in bioavailability of testosterone after androgen replacement therapy. Any measures to compensate for the variation in bioavailability of testosterone and presumably also other esterified drugs such as neuroleptic depot preparations, will improve the outcome of treatment and diminish the risk of side-effects. The effect of repeated testosterone administrations as in chronic treatment or abuse of anabolic androgenic steroids remains to be studied. In addition to polymorphisms in the androgen receptor known to modulate the androgenic effects [25] , we believe that genetic variation in the PDE7B gene also modulates the response to testosterone therapy or abuse.
Significant implications of genetic variation for interpretation of testosterone doping test results, were earlier founded by us for the UGT2B17 gene [8] . Individuals devoid of the UGT2B17 gene rarely reach the international accepted cut-off limit after testosterone injection in contrast to individuals expressing UGT2B17, who highly exceed the cut-off value. Here, we show the influence of yet another gene pathway on the T/E ratio. We show that the PDE7B genotype is associated with the excretion profile of testosterone and consequently the T/E ratio in UGT2B17 del/del individuals. Our result indicates that the PDE7B rs7774640 A allele is associated with faster excretion rate of testosterone compared with individuals homozygous for the G allele, which appear to excrete the testosterone slower and for a longer period of time. Thus it is conceivable that in UGT2B17 del/del participants, PDE7B G allele may yield an 'advantage genotype' further decreasing the risk of being identified as a doped subject. These findings need to be considered in the international doping test programs. Mean ( ± standard error of the mean) urinary testosterone glucuronide and epitestosterone glucuronide (T/E) levels in (a) individuals homozygous for the uridine 5 0 -diphospho-glucuronosyltransferase deletion (del/del; N = 16). (b) Individuals expressing UGT2B17 (ins/del and ins/ins; N = 36). Individuals homozygous for the phosphodiesterase G allele (striped bars) have lower T/E ratio compared with carriers of the A-allele (filled bars) for 5 days after testosterone administration. On days 13 and 15 the GG individuals display a higher T/E ratio in del/del individuals.
It is not known how the exogenous testosterone is metabolized in individuals homozygous for UGT2B17 deletion polymorphism (del/del). As del/del individuals have poor ability to excrete testosterone in the urine, it may be reasonable to think that they may have higher serum levels after administration. However, as shown here there was no association between the UGT2B17 genotype and serum levels of testosterone or the other androgen metabolites investigated. In contrast, a recent publication has described a correlation between the UGT2B17 polymorphism and the 5a-androstane-3a,17b-diol-glucuronides (= 3adiol-3G + 17G) [26] . We did not find such a relation in our study including 51 participants. It may be possible that in a larger sample population such a correlation would be detected.
Today, the urinary level of etiocholanolone sulphate is the only testosterone metabolite known to be significantly increased after testosterone administration in del/del individuals compared with individuals expressing the UGT2B17 gene (unpublished results). This increase is however not large enough to account for the difference between individuals with or without a functional UGT2B17 enzyme. The overall fate of testosterone in individuals devoid of the UGT2B17 enzyme is yet to be identified. Of note, the serum level of the 3a-Adiol-17G metabolite, which is known to be mainly glucuronidated by UGT2B17 [27] [28] [29] , was not associated with the UGT2B17gene deletion polymorphism, suggesting a shift to glucuronidation of this steroid substrate toward UGT2B15. In addition to UGT2B15, there are however other UGT enzymes known to exhibit 17-OH activity in vitro, namely UGTs 2B15, 2A2, 2A1, 1A10, 1A8 and 1A4 [30] . It is possible that the high load of testosterone induces the expression and/or activity of some of these UGTs in the del/del individuals and thereby compensates for the deficient capacity in del/del individuals to glucuronidate at position 17.
Other testosterone preparations than testosterone enanthate are available, that is, undecanoate, cypionate and propionate. In addition, many other anabolic androgenic steroids are provided as esters, for example, nandrolone decanoate, drostanolone propionate, trenbolone enanthate, etc. It is not known which enzymes catalyze the hydrolysis activity on these esters, but it is possible that PDE7B, or other PDE family members, may be involved. Importantly, a large number of other drugs are esterified with enanthate, for example, antipsychotic drugs (haloperidol, perfenazine, zuklopentixol, etc) and antiasthmatic drugs (flutikason, beklametason). Dose requirement and injection interval of these drugs differ widely between patients, and it is possible that genetic variation in the PDE pathway may contribute to this interindividual variation. This has great interest in clinical medicine, in particular in therapeutics with neuroleptic and androgenic drugs, and many drugs to be introduced in the market in the future.
